Dry eye disease (DED), keratoconjunctivitis sicca or dysfunctional tear syndrome, is the most
prevalent ophthalmic disease which affects a substantial segment of people worldwide with …

Dry eye disease (DED) is the most common ocular surface disease, characterized by
insufficient production and/or instability of the tear film. Tear substitutes are usually the first …

The low bioavailability and side effects of conventional drugs for eye disease necessitate the
development of efficient drug delivery systems. Accompanying the developments of …

Dry eye disease (DED) is a high prevalent multifactorial disease characterized by a lack of
homeostasis of the tear film which causes ocular surface inflammation, soreness, and visual …

Topical eyedrop application is the preferred route for drug delivery to anterior segment
tissues; however, the challenge of overcoming the eye's anatomical and physiological …

Dry eye disease (DED) is a multifactorial ocular surface disorder mutually promoted by
reactive oxygen species (ROS) and ocular surface inflammation. NLRP3 is the key regulator …

Extensive research is currently being conducted into novel ocular drug delivery systems
(ODDS) that are capable of surpassing the limitations associated with conventional …

Increasing endogenous tear film production via pharmacological neuroactivation of the
nasolacrimal reflex [NLR; also known as the trigeminal parasympathetic pathway (TPP)] is a …

Dry eye disease (DED) is a common disorder that remains challenging from a clinical
perspective. Unstable or deficient tear film is a major factor contributing to DED and the …

Dry eye disease is among the most prevalent diseases affecting the ocular surface. Artificial
tears remain the cornerstone therapy for its management. There are currently a wide variety …